Deal Details

Applied Therapeutics Announces $100 Million Private Placement

Healthcare

Applied Therapeutics private placement

Summary

Applied Therapeutics, Inc. (“Applied Therapeutics” or the "Company”) (NASDAQ: APLT) recently announced a private placement of 12,285,714 shares of its common stock at a price of $7.00 per share and 2,000,000 pre-funded warrants at a price of $6.999, generating gross proceeds of approximately $100 million, before deducting placement agent commissions and offering expenses.

The financing consisted of participation from new and existing institutional investors, including Perceptive Advisors, Janus Henderson Investors, Venrock Healthcare Capital Partners, Adage Capital Partners, Frazier Life Sciences, Logos Capital, Vestal Point Capital and Rock Springs Capital.

Baird served as a co-lead placement agent to Applied Therapeutics on this transaction.

About

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy. Applied Therapeutics headquartered in New York, New York.